Related Experiment Videos
BMS-232632 (Novartis/Bristol-Myers Squibb)
1Questcor Pharmaceuticals Inc, Hayward, CA 94545, USA. gwitherell@questcor.com
Current Opinion in Investigational Drugs (London, England : 2000)
|September 29, 2001
Summary
BMS-232632, an investigational HIV protease inhibitor, shows promise for treating HIV/AIDS. This azapeptide compound exhibits good antiviral activity and favorable pharmacokinetics, with potential for combination therapy.
Area of Science:
- Pharmacology
- Virology
- Drug Development
Background:
- BMS-232632 is an azapeptide HIV protease inhibitor developed by Bristol-Myers Squibb (BMS) under license from Novartis.
- It is a bis(L-tert-leucine) derivative belonging to a series of azadipeptide analogs, initially evaluated by Novartis against drug-resistant HIV strains.
Purpose of the Study:
- To evaluate the potential of BMS-232632 as a treatment for HIV/AIDS.
- To assess its antiviral activity, pharmacokinetic profile, and potential for combination therapy.
Main Methods:
- Preclinical evaluation of BMS-232632 and related compounds against drug-resistant HIV strains.
- Phase II clinical trials initiated by July 1999.
- Assessment of combination therapy with nucleoside analogs and other protease inhibitors.
Main Results:
- BMS-232632 demonstrated good antiviral activity and satisfactory pharmacokinetic profiles.
- The compound showed potential for use in combination with various antiretroviral agents.
- It is believed to possess a genotypic resistance profile distinct from other protease inhibitors.
Conclusions:
- BMS-232632 is a promising candidate for HIV/AIDS treatment.
- Its unique resistance profile may offer advantages in managing drug-resistant HIV infections.
- Further clinical development and NDA filing were anticipated by BMS.